Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

03:40
In the news release, GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025, issued 11-Feb-2025 by GC Biopharma over PR Newswire, we are advised by the company that the 2nd paragraph should read "WORLD Symposium 2025...

00:48
GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held from Feb. 3rd to 7th, 2025, in San Diego, USA....


10 february 2025

17:00
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced clinical trial updates for its lead asset, CONV01-? (225Ac-J591), a...

16:05
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation...

16:00
Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal...

12:00
The National Organization for Rare Disorders (NORD®) today published a new report on the critical role that leftover newborn screening samples play in public health and rare disease research....

10:00
Exactech, a global leader in medical technology, has announced the results of a new cadaveric study published in the Journal of Experimental Orthopaedics (JEO). The study highlights the superior reliability and reproducibility of Exactech's knee...

10:00
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient in the...

08:22
Hoth Therapeutics, Inc. , a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT....

08:12
Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement with Destum Partners, a leading advisory firm specializing in biopharma transactions. This strategic...

07:30
Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to transform diabetes care.Diabetes more than just a Metabolic Disorder: Diabetes is a multi-systemic disease impacting the central nervous system (CNS),...

07:00
Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic...

07:00
IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations of IVW-1001, a novel...

03:46
Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today the acceptance of an abstract for presentation at the prestigious American Society of Clinical Oncology, Genitourinary (ASCO-GU) Cancers Symposium conference, which will be held at the...

02:32
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product,...

01:15
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3.54.2% of participants in the CBL-514 group achieved at...

00:14
In a breakthrough for the advanced study of gut health, scientists from the National University of Singapore (NUS) have developed a 3D microscopic version of the human intestines condensed into a small chip about half the size of a five-cent coin....


9 february 2025

23:20
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in...

19:29
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first subject treated with an allogeneic BCMA CAR-T...


7 february 2025

20:14
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4R? monoclonal antibody, trade name:...

16:35
TheraSyn Bio (TSB), a Massachusetts-based synthetic biology enterprise specializing in precision...

13:27
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteriaGram-negative bacterial...

09:12
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatmentMean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment,...

09:00
Interim results demonstrate treatment with HMB-001 resulted in >50% reduction in treated bleeds at all tested dose levels In second oral presentation, Hemab presented first preclinical data for HMB-002, a potential novel treatment for Von...

07:00
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced...

07:00
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other...

06:45
Eli Lilly and Company announced results from the VIVID-2 open-label...

01:02
Brian T. Feeley, MD, FAAOS, was bestowed with the 2025 Kappa Delta Elizabeth Winston Lanier Award for his research in advancing the understanding of muscle degeneration in rotator cuff injuries and how it affects repair outcomes. Throughout the last...


6 february 2025

18:45
A new research study from the BC Centre for Excellence in HIV/AIDS (BC-CfE) shows that people with HIV (PWH) in British Columbia, Canada are now living much longer than just a few decades ago, but gains in life expectancy for women with HIV are...

11:59
Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today announced publication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH)....

11:00
Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation of new preclinical data for MTX-201, a bispecific antibody that antagonizes inhibitory KIR and promotes ICOS co-stimulation on...

10:00
The Global Coalition for Adaptive Research (GCAR) today announced that they are collaborating with Operational Medical Systems, part of the Defense Health Agency, to conduct an adaptive platform trial that is evaluating multiple pharmacotherapeutic...

09:30
The Conference Forum today announced the launch of the 9th annual Patients as Partners® Europe event, taking place on May 20-21, 2025 at Royal National Hotel in London, UK. The meeting offers an unparalleled...

09:15
The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded the $125,000 to Timothy C. Wang, MD, Chief, Division of Digestive and Liver Diseases, Silberberg...

09:00
Pykus Therapeutics, Inc., a clinical-stage medical technology company developing a novel retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair, today announced that it will present initial clinical data at the prestigious...

09:00
myTomorrows, a global health technology company connecting patients and physicians with all possible pre-approval treatment options, today announced the launch of its next-generation AI platform. Designed to streamline clinical trial recruitment, the...

08:30
PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today that senior company executives will present at five key industry conferences in the first half of 2025, demonstrating expertise in...

08:30
VolitionRx Limited Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" activation and inhibition in whole blood...

08:15
"Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster, life-saving decisions within the critical 'golden hour." A Melbourne...

08:00
BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the detection of active bowel inflammation in patients with Crohn's disease.BR55 is...

08:00
Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing...

08:00
A prospective randomized study published in BMJ Innovations found that Heartbeat Health's virtual-first cardiology program, when implemented after hospital discharge, significantly reduced cardiovascular readmissions and improved key health outcomes...

08:00
Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA)...

08:00
TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138,...

07:30
Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of its Phase 2 BMT-801 clinical study of...

03:30
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the...


5 february 2025

20:28
Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific...

17:03
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced today that the New England Journal of...

16:16
Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced the presentation of new clinical data at...

16:05
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial...

1 2 3 4 5 6 7 8 9 10